Literature DB >> 9755455

Transcription-factor-modulating agents: precision and selectivity in drug design.

A G Papavassiliou1.   

Abstract

Transcription factors play an important role in the long-term regulation of cell growth, differentiation and responses to environmental cues. There is growing evidence that these proteins are closely associated with control at the genetic level of the development and maintenance of the diseased state, and might therefore provide selective targets for novel pharmaceutical intervention. The vast array of information available on the three-dimensional structure of transcription factors and the intricate molecular machineries that fine-tune their activity offer opportunities for embarking on the rational design of drugs directed against specific transcription factors, thus producing potent new agents that modulate their function in a plethora of clinically important situations.

Mesh:

Substances:

Year:  1998        PMID: 9755455     DOI: 10.1016/s1357-4310(98)01303-3

Source DB:  PubMed          Journal:  Mol Med Today        ISSN: 1357-4310


  8 in total

1.  Clinical practice in the new era. A fusion of molecular biology and classical medicine is transforming the way we look at and treat diseases.

Authors:  A G Papavassiliou
Journal:  EMBO Rep       Date:  2001-02       Impact factor: 8.807

Review 2.  Drugging the undruggable: transcription therapy for cancer.

Authors:  Chunhong Yan; Paul J Higgins
Journal:  Biochim Biophys Acta       Date:  2012-11-09

3.  Design and characterization of decoy oligonucleotides containing locked nucleic acids.

Authors:  Rita Crinelli; Marzia Bianchi; Lucia Gentilini; Mauro Magnani
Journal:  Nucleic Acids Res       Date:  2002-06-01       Impact factor: 16.971

Review 4.  Transcription factor AP-2 and monoaminergic functions in the central nervous system.

Authors:  M Damberg
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

Review 5.  Transcription factor decoy oligonucleotide-based therapeutic strategy for renal disease.

Authors:  Naruya Tomita; Naoki Kashihara; Ryuichi Morishita
Journal:  Clin Exp Nephrol       Date:  2007-03-28       Impact factor: 2.801

6.  Transcription factor decoy oligonucleotides modified with locked nucleic acids: an in vitro study to reconcile biostability with binding affinity.

Authors:  Rita Crinelli; Marzia Bianchi; Lucia Gentilini; Linda Palma; Mads D Sørensen; Torsten Bryld; Ravindra B Babu; Khalil Arar; Jesper Wengel; Mauro Magnani
Journal:  Nucleic Acids Res       Date:  2004-03-29       Impact factor: 16.971

7.  Brainstem levels of transcription factor AP-2 in rat are changed after treatment with phenelzine, but not with citalopram.

Authors:  Cecilia Berggard; Mattias Damberg; Lars Oreland
Journal:  BMC Pharmacol       Date:  2005-01-21

8.  Phenelzine treatment increases transcription factor AP-2 levels in rat brain.

Authors:  Mattias Damberg; Cecilia Berggård; Lars Oreland
Journal:  BMC Pharmacol       Date:  2003-08-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.